Goldman Sachs
THTX

Goldman Sachs’s Theratechnologies THTX Stock Holding History

Goldman Sachs’s Portfolio THTX Stock Details THTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,225
Closed -$52.5K – 6652
2025
Q2 		$52.5K Buy
22,225
+5,200
+31% +$12.7K ﹤0.01% 5910
2025
Q1 		$23.8K Buy
+17,025
New +$28.4K ﹤0.01% 5937

Other funds holding THTX

JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CWP
Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GIP
Greatmark Investment Partners Columbus, Georgia $906M AUM 16.08% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM

Goldman Sachs's THTX Position: Q3 2025 in Review

Goldman Sachs sold out of Theratechnologies (THTX) in Q3 2025, closing a stake of 22,225 shares — an estimated $52.5K sold.

Goldman Sachs first reported a position in THTX in Q1 2025 and held it in 2 quarters. The position peaked at $52.5K in Q2 2025. 10 funds tracked by Wall St. Rank hold THTX as of Q3 2025.

  • Goldman Sachs reported no remaining Theratechnologies position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 22,225 Theratechnologies shares in Q3 2025, an estimated $52.5K.
  • Goldman Sachs first reported a position in Theratechnologies in Q1 2025 and held it in 2 quarters.
  • Goldman Sachs's Theratechnologies position peaked at $52.5K in Q2 2025.
  • 10 funds tracked by Wall St. Rank held Theratechnologies as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.